Rubifen Prolong® is a modified-release methylphenidate containing 50% MTF immediate release and 50% MTF extended release. It is indicated for the treatment of ADHD in children aged 6 years and older, adolescents and adults.
Access technical file RUBIFEN PROLONG® HARD CAPSULES OF MODIFIED RELEASE EFGRubifen Prolong® hard capsules of modified release EFG
Presentations: 10, 20, 30, 40, and 60 mg in a 30-tablet format in boxes with child-proof safety blister packs.
Administration: orally once a day in the morning, with or without food. Swallow the capsule whole. It can also be opened and the contents poured into soft food (such as applesauce) and administered immediately. The mixture must be taken immediately and should not be heated, chewed, or crushed.
The recommended initial dose is 20 mg.
The maximum daily dose in children is 60 mg and 80 mg in adults.
The information contained in this area is directed exclusively to healthcare professionals with the capacity to prescribe or dispense medications.
